ID Database Citation 9466980 Pubmed "Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. J Clin Invest. 1998 Feb 15;101(4):847–54. PubMed Europe PMC Scholia" 10197614 Pubmed "The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Morton CL, Wadkins RM, Danks MK, Potter PM. Cancer Res. 1999 Apr 1;59(7):1458–63. PubMed Europe PMC Scholia" 10220571 Pubmed "ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Chen ZS, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, et al. Mol Pharmacol. 1999 May;55(5):921–8. PubMed Europe PMC Scholia" 10815927 Pubmed "Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, et al. Clin Cancer Res. 2000 May;6(5):2012–20. PubMed Europe PMC Scholia" 11602529 Pubmed "A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4. Sai K, Kaniwa N, Ozawa S, Sawada JI. Drug Metab Dispos. 2001 Nov;29(11):1505–13. PubMed Europe PMC Scholia" 11990381 Pubmed "UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, et al. Pharmacogenomics J. 2002;2(1):43–7. PubMed Europe PMC Scholia" 12181437 Pubmed "Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Mol Pharmacol. 2002 Sep;62(3):608–17. PubMed Europe PMC Scholia" 12730278 Pubmed "Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N, Sai K, et al. J Pharmacol Exp Ther. 2003 Aug;306(2):688–93. PubMed Europe PMC Scholia" 12810652 Pubmed "Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Rajendra R, Gounder MK, Saleem A, Schellens JHM, Ross DD, Bates SE, et al. Cancer Res. 2003 Jun 15;63(12):3228–33. PubMed Europe PMC Scholia" 12893990 Pubmed "UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Desai AA, Innocenti F, Ratain MJ. Pharmacogenetics. 2003 Aug;13(8):517–23. PubMed Europe PMC Scholia" 12960109 Pubmed "Irinotecan pathway genotype analysis to predict pharmacokinetics. Mathijssen RHJ, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, et al. Clin Cancer Res. 2003 Aug 15;9(9):3246–53. PubMed Europe PMC Scholia" 14646693 Pubmed "Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, et al. Pharmacogenetics. 2003 Dec;13(12):741–57. PubMed Europe PMC Scholia" 15608127 Pubmed "Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Drug Metab Dispos. 2005 Mar;33(3):434–9. PubMed Europe PMC Scholia"